An antibody advancement company which is developing PG110 piroxicam.

Abbott to acquire the global rights to PanGenetics’ new therapeutic for treatment of chronic pain PanGenetics, an antibody advancement company which is developing PG110, a humanized antibody to Nerve Growth Aspect , today announced it has entered into an agreement with Abbott under which Abbott can acquire the global rights to this novel biologic piroxicam . PG110 happens to be in a Phase 1 clinical trial in sufferers with osteoarthritis and represents a promising brand-new therapeutic for the treatment of chronic pain. The contract contains an upfront payment of $170 million plus additional milestone payments, for a total as high as $190 million.